Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

被引：38

作者：

Tuccori, Marco ^{[1
]}

Focosi, Daniele ^{[2
]}

Blandizzi, Corrado ^{[1
,5
]}

Pelosini, Matteo ^{[2
]}

Montagnani, Sabrina ^{[1
,5
]}

Maggi, Fabrizio ^{[3
,4
]}

Pistello, Mauro ^{[3
,4
]}

Antonioli, Luca ^{[1
]}

Fornai, Matteo ^{[1
]}

Pepe, Pasquale ^{[6
]}

Rossi, Giuseppe ^{[6
]}

Petrini, Mario ^{[2
]}

机构：

[1] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy

[2] Univ Pisa, Div Haematol, Dept Oncol Transplantat & New Technol Med, Pisa, Italy

[3] Univ Pisa, Virol Sect, Pisa, Italy

[4] Univ Pisa, Retrovirus Ctr, Dept Expt Pathol, Pisa, Italy

[5] Tuscan Reg Ctr Pharmacovigilance, Pisa, Italy

[6] CNR, Unit Epidemiol & Biostat, Inst Clin Physiol, Pisa, Italy

来源：

ONCOLOGIST | 2010年 / 15卷 / 11期

关键词：

Rituximab; Progressive multifocal leukoencephalopathy; JCV; Monoclonal antibody; Non-Hodgkin's lymphoma; ADVERSE DRUG EVENTS; NATALIZUMAB; EFALIZUMAB; THERAPY; PROJECT; DISEASE; PML;

D O I：

10.1634/theoncologist.2010-0098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1-4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. The Oncologist 2010;15:1214-1219

引用

页码：1214 / 1219

页数：6

共 50 条

[1] Inclusion of rituximab in standard chemotherapy regimes for non-Hodgkin's lymphomas and risk of progressive multifocal leukoencephalopathy
Focosi, D.
Tuccori, M.
Blandizzi, C.
Maggi, F.
Pistello, M.
Montagnani, S.
Antonioli, L.
Fornal, M.
Pepe, P.
Petrini, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[2] Progressive multifocal leukoencephalopathy after rituximab in a case of non-hodgkin lymphoma
Kranick, Sarah M.
Mowry, Ellen M.
Rosenfeld, Myrna R.
NEUROLOGY, 2007, 69 (07) : 704 - 706
[3] Incidence of Progressive Multifocal Leukoencephalopathy in Non-Hodgkin Lymphoma Patients Treated with Rituximab
Focosi, Daniele
Tuccori, Marco
Blandizzi, Corrado
Del Tacca, Mario
Petrini, Mario
BLOOD, 2009, 114 (22) : 1416 - 1416
[4] Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab
Marco Tuccori
Daniele Focosi
Fabrizio Maggi
Mirco Cosottini
Barbara Meini
Fabio Lena
Corrado Blandizzi
Mario Del Tacca
Mario Petrini
Annals of Hematology, 2010, 89 : 519 - 522
[5] Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab
Paues, Jakob
Vrethem, Magnus
JOURNAL OF CLINICAL VIROLOGY, 2010, 48 (04) : 291 - 293
[6] Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab
Tuccori, Marco
Focosi, Daniele
Maggi, Fabrizio
Cosottini, Mirco
Meini, Barbara
Lena, Fabio
Blandizzi, Corrado
Del Tacca, Mario
Petrini, Mario
ANNALS OF HEMATOLOGY, 2010, 89 (05) : 519 - 522
[7] Progressive multifocal leukoencephalopathy in non-Hodgkin's lymphoma transplant patients
Avivi, I.
Tzoran, I.
Horowitz, N.
Zuckerman, T.
Oren, I.
Rowe, J. M.
BONE MARROW TRANSPLANTATION, 2011, 46 : S224 - S224
[8] Progressive Multifocal Leukoencephalopathy: A Survey on HIV-Negative Patients with Non-Hodgkin's Lymphoma Receiving Rituximab
Tuccori, M.
Focosi, D.
Montagnani, S.
Blandizzi, C.
Petrini, M.
Del Tacca, M.
DRUG SAFETY, 2009, 32 (10) : 895 - 895
[9] Rituximab in non-Hodgkin lymphomas
Rosolen, A.
Pillon, M.
Mussolin, L.
HEMATOLOGY REPORTS, 2010, 2 (01)
[10] Rituximab-associated Progressive Multifocal Leukoencephalopathy Derived from Non-Hodgkin Lymphoma: Neuropathological Findings and Results of Mefloquine Treatment
Sano, Yasuteru
Nakano, Yuta
Omoto, Masatoshi
Takao, Masaki
Ikeda, Eiji
Oga, Atsunori
Nakamichi, Kazuo
Saijo, Masayuki
Maoka, Takashi
Sano, Hironori
Kawai, Motoharu
Kanda, Takashi
INTERNAL MEDICINE, 2015, 54 (08) : 965 - 970

← 1 2 3 4 5 →